Personal Genome Diagnostics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Personal Genome Diagnostics Inc.
Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.
Quidel will pay $6bn for Ortho Clinical Diagnostics. Labcorp will acquire Personal Genome Diagnostics for $575m.
Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios
Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
- Contract Research Organization-CRO
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.